Delving into the Latest Updates on Anti-CD56 CAR T(The Affiliated Hospital of Xuzhou Medical University) with Synapse

Overview

Basic Info

Drug Type

CAR-T

Synonyms-

Target

CD56

Mechanism

CD56 inhibitors(Neural cell adhesion molecule 1 inhibitors), Immunologic cytotoxicity, T lymphocyte replacements

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [1]

Active Indication

Extranodal NK-T-Cell Lymphoma

Inactive Indication-

Originator Organization

Affiliated Hospital of Xuzhou Medical University

Active Organization

Affiliated Hospital of Xuzhou Medical University

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

This article describes about the anti-CD138 chimeric antigen receptor-modified T cell therapy for multiple myeloma with extensive extramedullary involvement in patients.¹⁸F-fluorodeoxyglucose positron emission tomog. (PET)-computed tomog. scanning showed increased ¹⁸F-fluorodeoxyglucose uptake in the nodule, stomach and thoracic vertebrae of a 52-yr-old man.Second-line treatment with lenalidomide was started and as expected the plasma cells in the bone marrow decreased significantly.This article concludes that Although the patient died due to lung infection, anti-CD138 CAR-T therapy may be a potential therapy in MM with extramedullary involvement.

100 Deals associated with Anti-CD56 CAR T(The Affiliated Hospital of Xuzhou Medical University)

Login to view more data